



SEQUENCE LISTING

<110> LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES
BIOTECHNOLOGIES
BOUREL, Dominique
GLACET, Arnaud
JORIEUX, Sylvie
STURA, Enrico
DUCANCEL, Frédéric
TEILLAUD, Jean-Luc

<120> USE OF METALLIC CATIONS TO IMPROVE FUNCTIONAL ACTIVITY
OF ANTIBODIES

<130> D 21 711 NT

<140> PCT/FR2004/002687

<141> 2004-10-20

<150> FR 03 12228

<151> 2003-10-20

<160> 2

<170> PatentIn version 3.3

<210> 1

<211> 1428

<212> DNA

<213> Homo sapiens

<220>

<223> cDNA sequence of double mutant His310-435Lys

<400> 1

atggagtttg ggctgagctg ggttttcctc gttgctcttt taagaggtgt ccagtgtcag	60
gtgcagctgg tggagtctgg gggaggcgtg gtccagcctg ggaggtccct gagactctcc	120
tgtacagcct ctggattcac cttcaaaaac tatgctatgc attgggtccg ccaggctcca	180
gccaaggggc tggagtgggt ggcaactata tcatatgatg gaaggaatat acaatatgca	240
gactccgtga agggccgatg caccttctcc agagacaatt ctcaggacac cctgtatctg	300
caactgaaca gcctcagacc ggaggacacg gctgtgtatt actgtgcgag acccgtaaga	360
agccgatggc tgcaattagg tcttgaagat gcttttcata tctggggcca ggggacaatg	420
gtcaccgtct cttcagcctc caccaagggc ccatcgggtct tccccctggc accctcctcc	480
aagagcacct ctggggggcac agcggccctg ggctgcctgg tcaaggacta cttccccgaa	540
ccggtgacgg tgtcgtggaa ctcaggcgcc ctgaccagcg gcgtgcacac cttcccggct	600
gtcctacagt cctcaggact ctactccctc agcagcgtgg tgaccgtgcc ctccagcagc	660
ttgggcaccc agacctacat ctgcaacgtg aatcacaagc ccagcaacac caaggtggac	720
aagaaagttg agcccaaate ttgtgacaaa actcacacat gccaccgtg cccagcacct	780

```

gaactcctgg ggggaccgtc agtcttcttc tccccccaa aaccaagga caccctcatg      840
atctccccga cccctgaggt cacatgcgtg gtggtggacg tgagccacga agaccctgag      900
gtcaagttca actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgcgg      960
gaggagcagt acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gaagcaggac     1020
tggctgaatg gcaaggagta caagtgcaag gtctccaaca aagccctccc agcccccatc     1080
gagaaaacca tctccaaagc caaagggcag ccccgagaac cacaggtgta caccctgccc     1140
ccatccccggg atgagctgac caagaaccag gtcagcctga cctgcctggg caaaggcttc     1200
tatcccagcg acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag     1260
accacgcctc cctgtctgga ctccgacggc tccttcttcc tctacagcaa gctcaccgtg     1320
gacaagagca ggtggcagca ggggaacgtc ttctcatgct cctgatgca tgaggctctg     1380
cacaacaagt acacgcagaa gagcctctcc ctgtctccgg gtaaatag                   1428

```

```

<210> 2
<211> 475
<212> PRT
<213> Homo sapiens

```

```

<220>
<223> Peptide sequence of double mutant His310-H435Lys.

```

```

<400> 2

```

```

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1           5           10           15

```

```

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
          20           25           30

```

```

Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe
          35           40           45

```

```

Lys Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Ala Lys Gly Leu
          50           55           60

```

```

Glu Trp Val Ala Thr Ile Ser Tyr Asp Gly Arg Asn Ile Gln Tyr Ala
65           70           75           80

```

```

Asp Ser Val Lys Gly Arg Cys Thr Phe Ser Arg Asp Asn Ser Gln Asp
          85           90           95

```

```

Thr Leu Tyr Leu Gln Leu Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
          100          105          110

```

Tyr Tyr Cys Ala Arg Pro Val Arg Ser Arg Trp Leu Gln Leu Gly Leu
 115 120 125

Glu Asp Ala Phe His Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser
 130 135 140

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
 145 150 155 160

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
 165 170 175

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
 180 185 190

Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
 195 200 205

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
 210 215 220

Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
 225 230 235 240

Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
 245 250 255

Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
 260 265 270

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
 275 280 285

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
 290 295 300

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
 305 310 315 320

Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
 325 330 335

Leu Lys Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
 340 345 350

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
 355 360 365

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp
 370 375 380

Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
 385 390 395 400

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
 405 410 415

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
 420 425 430

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
 435 440 445

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Lys Tyr
 450 455 460

Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 465 470 475